91results about How to "Reduce liver toxicity" patented technology

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.

The invention discloses an amphipathy block-polymer hydroxyethyl-starch-olylactic-acid copolymer and a preparing method and nanometer medicine loading system thereof. The method includes the steps that 4-dimethylaminopyridine serves as a catalyst, N-N'-dicyclohexylcarbodiimide serves as a dehydrating agent, carboxyl at the tail end of polylactic acid and hydroxyl on hydroxyethyl-starch sugar ring are subjected o an esterification reaction, hydrophobic polylactic acid is coupled on hydrophilic hydroxyethyl starch accordingly, and the amphipathy hydroxyethyl-starch-polylactic-acid block polymer is synthesized. Debydrochlorination adriamycin amycin is loaded to a hydrophobic core with the emulsified solvent evaporation method and the high pressure homogenization technology, evenly-distributed medicine loading polymer nanometer particles with the particle-size of about 140 nm are formed, and are applied in preparing antitumor medicine, the medicine in-vivo cycling time is prolonged, the toxic and side effects of the medicine are reduced, and the good antitumor effect is achieved.

The present invention comprises compositions comprising combinations of compositions of extracts of kava mate' extract compositions or theobromine. The invention further comprises methods for treating conditions related to mental and physical fatigue, anxiety, muscle tension, nervous depression, headache, obesity, and mild pain as well a enhancement of cognition and mental focus comprising administering effective amounts of the compositions of the present invention.

The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. New compounds and methods for treating these conditions are disclosed. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation.

The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.

The invention belongs to the medicine field, and relates to tacrine-pyridinothiophene compounds and applications thereof. The saccharides of tacrine-pyridinothiophene compounds have activity on inhibiting kinase-3beta acetyl cholinesterase dual targets. The compounds can be used as a precursor for preventing Alzheimer's disease by inhibiting the activity of cholinesterase.

A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.

The present invention comprises compositions comprising combinations of kava extract compositions in combination with one or more anxiolytics and methods for treating conditions related to the various anxiety disorders comprising administering the compositions of the present invention. The invention further provides methods for enhancing the therapeutic activity of an anxiolytic comprising administering the anxiolyitc in combination with extract of Piper methysticin.

The present invention discloses 3-vinyl-quinoxaline-2(1H)-one derivative acting on FGFR-1, a preparation method and uses thereof, and belongs to the field of pharmaceutical chemistry. According to the present invention, o-phenylenediamine and pyruvic acid are adopted as raw materials and are subjected to cyclization to obtain 3-methyl quinoxaline-2(1H)-one, the 3-methyl quinoxaline-2(1H)-one reacts with different substituted aldehydes to obtain 3-substituted quinoxaline derivatives, and the 3-substituted quinoxaline derivatives are adopted as the intermediate products and are subjected to substitution to obtain other types of the target compounds, wherein the 6 new compounds are prepared; and the 3-vinyl-quinoxaline-2(1H)-one derivatives of the present invention have a certain inhibition effect for experiment cells, show a certain anti-tumor activity, and further have characteristics of cell selectively, good safety, and kinase inhibition activity.

The invention discloses a pharmaceutical composition for treating diabetes and complication thereof, and particularly relates to a composition containing arctigenin and PioglitaZone or pharmaceutically acceptable salts thereof and to the purpose of the composition in preparing medicines for treating diabetes, diabetic complication and diseases related to diabetes.

A pharmaceutical composition for treating tuberculotic diseases with no side effect / low side effect is provided by the present invention, which pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents.

The present invention relates to a series of phosphoryl-containing steroidal compounds, a preparation method and an application thereof, in particular to the compounds as a formula I, an isomer, pharmaceutically acceptable salts or chemically protected forms thereof, the preparation method thereof, and the application of the compounds in preparation of a medicine for treating cancer-related diseases. The compounds of the present invention have the good activity for inhibiting malignant tumors such as melanoma and prostate cancer.

The present invention is directed to the reduction of acetaminophen toxicity by dietary milk thistle extract. Milk thistle has been reported to have protective effects on the liver and to greatly improve its function. It is typically used to treat liver cirrhosis, chronic hepatitis (liver inflammation), and toxin-induced liver damage. The present invention, for the first time, combines milk thistle and acetaminophen in a unique and novel way to provide single dosages containing both ingredients, whether dispensed in a liquid suspension, chewable tablets, coated caplets, gelcaps, geltabs, and suppositories.

The invention belongs to the field of medicine research and development, and particularly relates to a compound and application in an anti-tumor medicine thereof. The compound is prepared from a platiniferous anti-tumor compound and a chelating agent, wherein the chelating agent is sodium(S)-2-(dithiocarboxylic acid((2S,3R,4R,5R)-2,3,4,5,6-pentacarbonyl hexyl)amino)-4-(methylmercapto)butyrate. Theinvention further provides application of the compound in the anti-tumor medicine. Through experiment examination, the chelating agent in the compound can effectively chelate heavy metal in the platiniferous anti-tumor compound, so that multiple adverse reaction during exclusive use of the platiniferous compound is effectively reduced, the dosage of the platiniferous anti-tumor compound can be improved, and an anti-tumor effect is optimized; meanwhile, the chelating agent is non-toxic, and has no toxic effects on normal cells; and the technical defects that in the prior art, when the platiniferous anti-tumor compound is used for medication, adverse reaction is large, and medicine resistance is liable to be generated are solved.

The invention belongs to the technical field of medicine and relates to a pharmaceutical composition with liver protective function. The pharmaceutical composition is composed of saikoside A and taurine; the composition is prepared by supplementing the routine pharmaceutical adjuvants in a routine process. The invention further discloses application of the pharmaceutical composition in preparation of a medicine for treating and / or preventing the acute liver injury or relieving the chronic liver injury. The pharmaceutical composition has an obvious effect for preventing the acute liver injury or reducing the chronic liver injury.

The invention belongs to the field of extraction of natural products of plants and in particular relates to a preparation method and application of a macadamia nut leaf extract. The preparation methodcomprises steps of ultrasonic-assisted water extraction and alcohol precipitation, in addition, phenolic acid substances are removed through gel column chromatography, desalting treatment is furtherimplemented, and the macadamia nut leaf extract which is high in polysaccharide content and free of phenolic acid substance is obtained. By adopting the extraction method, conditions can be provided for comprehensive utilization of macadamia nut leaves, and a great amount of leaf resources are not discarded any longer but being adopted to prepare foods or healthcare products with plant polysaccharides.

The invention discloses a freeze-dried (R)-lansoprazole powder injection. The freeze-dried (R)-lansoprazole powder injection contains (R)-lansoprazole, mannitol, meglumine and sodium hydroxide, wherein the content of (R)-lansoprazole is 10-30 mg. Through research on the dosage of a prescription and a freeze-drying process, a sample with good appearance, qualified water residue content and good resolubility is obtained. The results of experiments on rats about acute toxicity, tolerability and safety verify that the freeze-dried (R)-lansoprazole powder injection of the invention has good tolerability and safety and few adverse reactions, and is more applicable to preparation of drugs used for treating upper gastrointestinal hemorrhage caused by peptic ulcers.

The invention belongs to the field of pharmaceutical production and application and particularly discloses a preparation method and application of a drug or health product for treatment of liver injury. Pharmacological experiments show that the drug has the effects of significantly improving jasmine-induced hepatoxicity, reducing activity of mice serum ALT and AST of CCL4 chemical liver injury, reducing the level of mice serum ALT and AST of BCG and lipopolysaccharide induced immunological liver injury, and significantly protecting the liver. Medicinal materials in the drug belong to TCMs as food and drug, so that the drug can be made into drugs or health products for the treatment of liver injury.

Disclosed is an Edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a co-solvent based formulation.

The instant invention provides for novel cationic lipids of Formula A that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The invention discloses an anticancer composition and application of the anticancer composition to preparation of drugs. The anticancer composition comprises silybin and chemotherapeutic drugs. Test results show that the combined application of silybin and chemotherapeutic drugs to preparation of drugs for resisting human ovarian cancer drug-resistant cells is capable of effectively improving thesensibility of the human ovarian cancer drug-resistant cells to the chemotherapeutic drugs and reducing hepatotoxicity induced by the chemotherapeutic drugs.

The invention provides a blood-supplying nutritious oral solution for the livers of pets and a production process thereof. The blood-supplying nutritious oral solution includes a nutritious oral solution; and the nutritious oral solution includes active polypeptide, propolis, ferrous ions, fish oil, unsaturated fatty acid, vitamins and amino acids. The blood-supplying nutritious oral solution andproduction process thereof have the efficacy of activating the regeneration of hepatic cells, promoting the DNA synthesis of the hepatic cells, enhancing immunity and promoting liver hematopoiesis andblood storage by adopting a small molecule amino acid extracted from pig haslet; the flavonoid and other substances in the propolis have strong protection effects on livers, so that liver toxins canbe relieved, and liver poisoning can be alleviated; the lignans in the propolis can improve the influence of toxic substances on the livers; and suspension embedding can be performed on ferrous iron so as to make the ferrous iron become slightly soluble nanoparticles, so that the problems of oxidation and precipitation can be solved.